Skip to search formSkip to main contentSkip to account menu

nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… 
National Institutes of Health

Related topics

Related topics

6 relations
10 ML nivolumab 10 MG/ML Injection [Opdivo]Monoclonal AntibodiesNCIt Antineoplastic Agent Terminologyantigen binding

Broader (1)

Antineoplastic Agents

Narrower (1)

MDX-1106

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
486 Background: In HCC, surgical resection is associated with high recurrence rates, and no effective neoadjuvant or adjuvant… 
2018
2018
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation
Background: Outcomes of patients (pts) with Richter transformation (RT) remain dismal with a median survival of less than 1… 
2017
2017
EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer
With the expansion of immunotherapy in the treatment of lung cancer, clinicians have to face new clinical pictures and adapt… 
2017
2017
A case of new‐onset antibody‐positive myasthenia gravis in a patient treated with pembrolizumab for melanoma
1. Becker PE. Myotonia congenita and syndromes associated with myotonia: clinical-genetic studies of the nondystrophic myotonias… 
Highly Cited
2016
Highly Cited
2016
Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
Background: In previously treated MEL patients (pts), the results of an early phase I trial with NIVO monotherapy (CA209-003… 
Highly Cited
2016
Highly Cited
2016
A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)
INTRODUCTION: Outcomes of pts with MDS after hypomethylating agent (HMA) failure remain poor. Improving the response and survival… 
2016
2016
Nivolumab-induced thyroid dysfunction.
Nivolumab (ONO-4538) is an anti-programmed death-1 specific monoclonal antibody, which has become a standard treatment for… 
Highly Cited
2016
Highly Cited
2016
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
6 Background: Patients (pts) with GC/GEC often present with A/M disease, which has a poor prognosis, with 1-year survival < 30… 
Highly Cited
2014
Highly Cited
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in… 
2013
2013
Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)